Arnold Monto (born March 22, 1933) is an American physician and epidemiologist. At the University of Michigan School of Public Health, Monto is the Thomas Francis, Jr. Collegiate Professor Emeritus of Public Health, professor emeritus of both epidemiology and global public health, and co-director of the Michigan Center for Respiratory Virus Research & Response.[3] His research focuses on the occurrence, prevention, and treatment of viralrespiratory infections in industrialized and developing countries' populations.
Monto fulfilled his national service commitment in the Virus Diseases Section of the Middle America Research Unit: a part of the National Institute of Allergy and Infectious Diseases. While there, he began his career-long interest in respiratory illnesses; confirming that the same viruses causing illnesses in the temperate zones cause illnesses in the tropics.[3] He was among the first to observe that influenza viruses, in areas where temperatures were stable year-round, mainly occurred in the rainy season.[7] In 1965, Monto was recruited to the University of Michigan School of Public Health by Thomas Francis Jr., chair of and professor in the school's Department of Epidemiology. Monto rose through the academic ranks from research associate to professor. He served as chair of the school's Department of Population Planning and International Health from 1993 to 1996 and as director of the University of Michigan Center for Population Planning.[8] From 2002 to 2004, Monto was director of the University of Michigan Bioterrorism Preparedness Initiative.[9] In 2010, he was named the Thomas Francis Collegiate Professor of Public Health.[10] He is the founder and director of the University of Michigan-Israel Public Health Partnership for Collaborative Research and Education (2014–present) and is co-director of the Michigan Center for Respiratory Virus Research and Response, one of five centers across the country that collects data for the Centers for Disease Control and Prevention.[11][12] Monto spent periods as a visiting scientist at Northwick Park Hospital Clinical Research Center in Harrow, England; at the World Health Organization in Geneva, working on implications of lower respiratory tract infections globally; and at the National Research Council, Washington, D.C. organizing studies of the causes of respiratory infections in low-resourced countries.
He is the author of over 350 research papers[when?] focusing mainly on the epidemiology and implications of respiratory infections, and co-editor of the Textbook of Influenza–Second Edition.[13]
In 2015, the U.S. Centers for Disease Control and Prevention established the annual "Arnold S. Monto Award" in honor of Monto for innovation in epidemiology and vaccinology. "Dr. Monto's work has helped us understand the value of measuring vaccine effectiveness in the communities where vaccines are used and taking that data to help enhance influenza prevention programs", said Joe Bresee, Chief of the Epidemiology and Prevention Branch of CDC's Influenza Division."[18]
Throughout his career, Monto has focused on the occurrence, prevention, and control of respiratory infections, with a particular interest in influenza. At the University of Michigan in 1965, he developed the Tecumseh Study of Respiratory Illness, which described the specific viruses involved in causing illnesses in American families over an 11-year period.[20] During the 1968 influenza pandemic, he found that vaccinating school-age children reduced infection in the entire community, an early demonstration of herd immunity.[21] Subsequently, he was involved in evaluating a variety of strategies to control influenza including vaccines, antivirals, and non-pharmaceutical interventions such as antiseptic tissues and face masks.[22] In particular, he designed and carried out critical studies evaluating the value of the neuraminidase inhibitors now in use for influenza. In the 2000s he was involved in developing pandemic control strategies including social distancing, leading to work at WHO and in the US during the 2009 swine flu pandemic.[23] He also led clinical trials establishing the superiority of inactivated vaccines compared to live attenuated vaccines in preventing influenza in adults.[24]
In 2010, Monto returned to the study of respiratory illnesses in families with the establishment of the Household Influenza Vaccine Evaluation (HIVE) Study. The design is a comprehensive one, allowing researchers to study many aspects of infection occurrence and prevention over time. The study has resulted in several notable findings related to natural infection with different viruses and the immune correlates of protection from different influenza vaccines. It was the first to demonstrate the potential problems with the serial use of such vaccines.[25] These issues are now being addressed as part of the Universal Influenza Vaccine Program.[26][27] Monto was the plenary speaker for a 2017 NIH-led workshop of U.S. and international experts from academia, industry, and government to develop a strategic plan and research agenda aimed at the development of a universal influenza vaccine.[28] The design also allows study over time of other respiratory viruses including the coronaviruses. Monto is involved in other studies assessing influenza vaccine effectiveness in preventing medical encounters and hospitalization with a goal of improving protection.[29] A study in progress addresses the role of antivirals in seasonal and pandemic influenza control.
Selected service, international and national
Pandemic Influenza Task Force, Infectious Disease Society of America, 2007–present[30]
Board Member, European Scientific Working Group on Influenza, 2009–2016[31]
WHO Influenza Pandemic Emergency Committee, 2009–2010[32]
Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, Crisp A (July 1999). "Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial". JAMA. 282 (1): 31–5. doi:10.1001/jama.282.1.31. PMID10404908.
1 2 Monto, AS (1967). "A community study of respiratory infections in the tropics I Description of the community and observations on the activity of certain respiratory agents". American Journal of Epidemiology. 86 (1): 78–92. doi:10.1093/oxfordjournals.aje.a120735. PMID4951566.
↑ monto, arnold (1 June 1959). "The Liver in Ulcerative Disease of the Intestinal Tract: Functional and Anatomic Changes". Annals of Internal Medicine. 50 (6): 1385–94. doi:10.7326/0003-4819-50-6-1385. PMID13661766.
↑ monto, AS; Rantz, LA (1 August 1963). "The development and character of bacteriuria in pregnancy". Annals of Internal Medicine. 59 (2): 186–93. doi:10.7326/0003-4819-59-2-186. PMID14049347.
↑ Monto, AS; Koopman, JS; Longini, IM (1985). "Tecumseh study of illness XIII Influenza infection and disease, 1976-1981". American Journal of Epidemiology. 121 (6): 811–22. doi:10.1093/oxfordjournals.aje.a114052. PMID4014174.
↑ Monto, AS; Olazabal, F (1966). "Asian influenza in the Panama Canal zone: isolation of a virus variant and protective effect of a vaccine containing A2/Japan/305/57". American Journal of Epidemiology. 83 (Jan): 101–12. doi:10.1093/oxfordjournals.aje.a120558. PMID5910213.
↑ Monto, AS (2005). "The threat of an avian influenza pandemic". New England Journal of Medicine. 352 (4): 323–5. doi:10.1056/NEJMp048343. PMID15668220.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
